News and InfoDec 2016
3011, 2021

“Still alive and kicking” – The importance of sickle cell disease clinical trial awareness

By |November 30th, 2021|Clinical Trial Awareness Recruitment, Patient Communities, Patient Insights|1 Comment

"Still alive and kicking" - The importance of sickle cell disease clinical trial awareness By Kathleen Hoffman, PhD, MSPH Sickle cell disease (SCD) is a rare disease: an inherited and incurable blood disorder that causes red blood cells to be misshapen and rigid, affecting their ability to provide oxygen to tissues. Their shape and rigidity cause random blood vessel inflammation and blockages anywhere in the body, with [...]

1611, 2021

New classes of psoriatic arthritis drugs in clinical trials show promise

By |November 16th, 2021|Patient Communities, Patient Insights|0 Comments

New classes of psoriatic arthritis drugs in clinical trials show promise By Kathleen Hoffman, PhD, MSPH Psoriatic Arthritis (PsA) is an inflammatory autoimmune disease affecting approximately one to two percent of the population. While psoriasis causes red and scaly patches on the skin, PsA creates mild to severe pain and swelling of any joint. About 5 to 30 percent of patients with psoriasis eventually develop PsA, and [...]

911, 2021

Epilepsy can happen to anyone at any age

By |November 9th, 2021|Marketing, Patient Communities, Patient Insights|0 Comments

Epilepsy can happen to anyone at any age By Kathleen Hoffman, PhD, MSPH Seizures are frightening for those who have them, for their loved ones and for onlookers. Descriptions of epilepsy go back as far as the Sumerians in 2500 BC. Expressing awe and dread, Babylonians, in 1050 BC, called seizures “​​ṣibtu” translated as “possession” and ṣabātu, “to seize” as in being possessed or seized by the [...]

211, 2021

Phase II studies for Non-Hodgkin Lymphoma show promise

By |November 2nd, 2021|Marketing, Patient Insights|0 Comments

Phase II studies for Non-Hodgkin Lymphoma show promise By Kathleen Hoffman, PhD, MSPH Let’s talk about lymphoma: Cancer of the lymphocytes, formed in the bone marrow and thymus that circulate in the lymph system. A previous post covered updates on research and treatments of Hodgkin Lymphoma, a cancer characterized by the presence of abnormal cells called “Reed-Sternberg” cells.1 Non Hodgkin Lymphoma (NHL) is any type of lymphoma [...]

2610, 2021

Hope for Patients with Early Alzheimer’s Disease and Their Family Members

By |October 26th, 2021|Marketing, Patient Insights|0 Comments

Hope for Patients with Early Alzheimer’s Disease and Their Family Members By Kathleen Hoffman, PhD, MSPH Losing who you are is essentially what the diagnosis of Alzheimer’s disease means. An irreversible and progressive brain disorder, it is the sixth leading cause of death, affecting over 6 million people in the US.1 The disease profoundly impacts those who are diagnosed as well as their loved ones: I am [...]

1910, 2021

From Treatment Desert to Blooming Field of Breakthroughs: Multiple Sclerosis

By |October 19th, 2021|Marketing, Patient Insights|0 Comments

From Treatment Desert to Blooming Field of Breakthroughs: Multiple Sclerosis By Kathleen Hoffman, PhD, MSPH Research prior to 2019 underestimated the prevalence of neurological diseases, and specifically Multiple Sclerosis (MS) by over one-half. A new algorithm, including health insurance claims data, determined that the population suffering from MS was not around 400,000 but actually closer to one million (913,925).1,2 This discovery continues the forward progress begun in [...]

1210, 2021

Updates from ASCO and ESMO 2021 Add to Successes in Hodgkin Lymphoma Research and Treatment

By |October 12th, 2021|Patient Communities, Patient Insights|0 Comments

Updates from ASCO and ESMO 2021 Add to Successes in Hodgkin Lymphoma Research and Treatment By Kathleen Hoffman, PhD, MSPH In 1832 Sir Thomas Hodgkin described a morbid condition of the glands and spleen which in 1865 was named Hodgkin disease by Samuel Wilkes. It was a fatal disease. Yet it has become, as this Inspire patient describes, highly treatable.1 my first oncologist, trying to reassure me [...]

510, 2021

Will New Medication Guidelines For Rheumatoid Arthritis Improve Patient Satisfaction With Treatment?

By |October 5th, 2021|Marketing, Patient Insights|0 Comments

Will New Medication Guidelines For Rheumatoid Arthritis Improve Patient Satisfaction With Treatment? By Kathleen Hoffman, PhD, MSPH Despite the advances and diversification of disease modifying antirheumatic drugs (DMARDs) to treat rheumatoid arthritis (RA), a recent report surveying current RA patients showed that the majority are not satisfied with their treatment experience. In a study of 258 patients, all of whom were taking at least 1 DMARD, only [...]

2809, 2021

What Are Patients and Caregivers Talking About? Lung Cancer Biomarkers

By |September 28th, 2021|Clinical Trials, HEOR, Marketing, Patient Engagement, Patient Insights|0 Comments

What Are Patients and Caregivers Talking About? Lung Cancer Biomarkers By Kathleen Hoffman, PhD, MSPH Since the FDA approved the first targeted treatment for NSCLC in 2003, treatment decisions for NSCLC are increasingly made based on individual genomics.1,2  There are now 20 distinct biomarkers that serve as identification points differentiating cancer cells from healthy cells and distinguishing one expression of cancer from another. Science has progressed from [...]

2109, 2021

Impressive Advances in Treating Chronic Lymphocytic Leukemia

By |September 21st, 2021|Patient Communities, Patient Insights|0 Comments

Impressive Advances in Treating Chronic Lymphocytic Leukemia By Kathleen Hoffman, PhD, MSPH Chronic Lymphocytic Leukemia (CLL) is the most prevalent form of adult leukemia, with about 20,000 new diagnoses per year in the United States alone.1  While it can occur at earlier ages, it is primarily a disease of older adults, with 70 years as the average age at diagnosis. Most of those who are diagnosed have [...]